Wang Shen-Yu, Liu Wen-Qing, Li Yu-Qing, Li Jing-Xin, Zhu Feng-Cai
Department of Immunization Programe, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.
Expert Rev Vaccines. 2023 Jan-Dec;22(1):704-713. doi: 10.1080/14760584.2023.2242528.
The global spread of COVID-19 has prompted the development of vaccines. A recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) developed by Chinese scientists has been authorized for use as a prime and booster dose in China and several other countries.
We searched published articles as of 4 May 2023, on PubMed using keywords related to Adenovirus vector, vaccine, and SARS-CoV-2. We reported the progress and outcomes of Ad5-nCov, including vaccine efficacy, safety, immunogenicity based on pre-clinical trials, clinical trials, and real-world studies for primary and booster doses.
Ad5-nCoV is a significant advancement in Chinese vaccine development technology. Evidence from clinical trials and real-world studies has demonstrated well-tolerated, highly immunogenic, and efficacy of Ad5-nCoV in preventing severe/critical COVID-19. Aerosolized Ad5-nCoV, given via a novel route, could elicit mucosal immunity and improve the vaccine efficacy, enhance the production capacity and availability, and reduce the potential negative impact of preexisting antibodies. However, additional research is necessary to evaluate the long-term safety and immunogenicity of Ad5-nCoV, its efficacy against emerging variants, its effectiveness in a real-world context of hybrid immunity, and its cost-effectiveness, particularly with respect to aerosolized Ad5-nCoV.
新冠病毒病（COVID-19）的全球传播促使了疫苗的研发。中国科学家研发的重组5型腺病毒载体COVID-19疫苗（Ad5-nCoV）已在中国和其他几个国家被批准用于初免和加强免疫接种。
我们检索了截至2023年5月4日在PubMed上发表的文章，使用了与腺病毒载体、疫苗和严重急性呼吸综合征冠状病毒2（SARS-CoV-2）相关的关键词。我们报告了Ad5-nCov的进展和结果，包括基于临床前试验、临床试验以及初免和加强免疫接种的真实世界研究的疫苗效力、安全性、免疫原性。
Ad5-nCoV是中国疫苗研发技术的一项重大进展。临床试验和真实世界研究的证据表明，Ad5-nCoV耐受性良好、免疫原性高，且在预防重度/危重型COVID-19方面有效。通过一种新途径给予雾化Ad5-nCoV可引发黏膜免疫并提高疫苗效力，增强生产能力和可及性，并减少预先存在抗体的潜在负面影响。然而，有必要开展更多研究以评估Ad5-nCoV的长期安全性和免疫原性、其对新出现变异株的效力、其在混合免疫真实世界背景下的有效性以及其成本效益，特别是关于雾化Ad5-nCoV的情况。
